This is in concordance with recent findings illustrating the regulatory role of CLDN1 in the metabolism of pancreatic cancer cells, which in turn has a significant impact on their sensitivity to certain chemotherapies [42]. This evidence concerns the gene CLDN1 and familial pancreatic carcinoma.